As per MRFR analysis, the India hERG Screening Market Size was estimated at 50 (USD Million) in 2023. The India hERG Screening Market Industry is expected to grow from 56(USD Million) in 2024 to 280 (USD Million) by 2035. The India hERG Screening Market CAGR (growth rate) is expected to be around 15.756% during the forecast period (2025 - 2035).
The India hERG Screening Market is undergoing substantial growth, which is being fueled by a variety of factors. The rising prevalence of cardiac diseases has resulted in a greater demand for effective screening methods. This is one of the primary market drivers. The necessity of HERG Screening in pharmaceutical development has increased due to the increasing awareness of the significance of drug safety and the regulatory requirements established by agencies such as the Central Drugs Standard Control Organization (CDSCO). Furthermore, there is an increasing emphasis on personalized medicine, which underscores the importance of conducting thorough testing on new compounds to guarantee patient safety.Â
Consequently, a greater number of biotech and pharmaceutical companies are participating in HERG Screening processes. The India hERG Screening Market is experiencing a growth in opportunities as new technologies and platforms are introduced. The accuracy and efficiency of HERG channel assessments can be significantly enhanced through the incorporation of artificial intelligence and machine learning in screening processes. Additionally, the development of innovative screening solutions that are specifically designed to comply with local regulatory standards can be facilitated by partnerships between research institutions and industry stakeholders.Â
Recently, there has been a discernible trend toward the adoption of in vitro testing methodologies that are cost-effective and in accordance with global standards. India's dynamic healthcare ecosystem is adjusting to international research practices, and these developments are well-received.The burgeoning market for HERG Screening services in India is reflected in the growing number of contract research organizations (CROs).Â
These organizations are capable of assisting both local and multinational pharmaceutical companies in their efforts to accelerate their drug development processes. In general, the future of the HERG Screening Market in India is being influenced by the emphasis on patient safety, technological advancements, and a favorable regulatory environment.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Increasing Focus on Cardiac Safety in Drug Development
The India hERG Screening Market Industry is witnessing significant growth due to the increasing focus on cardiac safety assessments in drug development processes. With the rising prevalence of cardiovascular diseases (CVDs) in India, which affects approximately 54% of adult deaths, as reported by the National Health Mission of India, pharmaceutical companies are mandated to ensure the safety of their products. This has led to an increased demand for HERG (Human Ether-a-go-go-Related Gene) screening, which is crucial for identifying potential cardiac liabilities in drug candidates.
Established organizations like Sun Pharmaceutical Industries and Cipla are investing heavily in Research and Development to enhance their screening capabilities, thereby supporting the growth of this market. Furthermore, regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) are emphasizing stringent safety protocols, thereby reinforcing the importance of HERG assays in drug approval processes.
Rising Incidence of Arrhythmia and Other Cardiovascular Disorders
The rising incidence of arrhythmia and other cardiovascular disorders in India is a significant driver for the India hERG Screening Market Industry. According to the Indian Heart Association, around 30% of Indians suffer from some form of cardiovascular disease, leading to an increased need for effective screening methods. The emphasis on early detection and management of heart conditions is motivating healthcare professionals to utilize HERG Screening as a standard practice during drug development.
Additionally, pharmaceutical companies are collaborating with healthcare providers to improve patient outcomes by leveraging advanced HERG Screening technologies, which are further accelerating market growth.
Increased Regulatory Requirements and Guidelines
The India hERG Screening Market Industry is also propelled by increased regulatory requirements and guidelines set forth by national and international health authorities. With the World Health Organization highlighting the need for robust cardiotoxicity testing, Indian regulatory bodies are closely following these global practices. New guidelines require drug manufacturers to conduct HERG Screening as part of the preclinical testing phase. This regulatory landscape has led companies to invest in HERG Screening technologies to comply with these guidelines.
For instance, organizations like Dr. Reddy's Laboratories are optimizing their R&D functions to meet these regulatory expectations, thereby driving demand within the India hERG Screening Market.
The India hERG Screening Market has shown robust dynamics primarily around the Type segment, which includes essential categories like Gene KCNH2 and Mutant KCNH2. As the focus on cardiac safety continues to grow, the relevance of Gene KCNH2 has surged within the biotechnology and pharmaceutical sectors. This gene plays a crucial role in encoding potassium channels that are vital for cardiac repolarization, directly influencing the heart's electrical activity. Given India's increasing prevalence of cardiovascular diseases, there is a compelling drive for accurate HERG Screening to mitigate the risks associated with drug-induced arrhythmias.Â
Meanwhile, Mutant KCNH2 has gained considerable attention due to its association with various genetic disorders, including long QT syndrome. Such mutations can lead to life-threatening cardiac events, underscoring the necessity for HERG Screening in clinical testing and personalized medicine initiatives in India. The growing incidence of such genetic disorders in the population has fueled research investments and development programs aimed at improving HERG Screening methodologies. Both Gene KCNH2 and Mutant KCNH2 are significant in the evolving landscape of the India hERG Screening Market, driven by increased regulatory scrutiny and a rising demand for safety assessments in drug development.Â
With government bodies and health organizations emphasizing the importance of cardiac monitoring, these segments are poised to dominate the market landscape. The integration of advanced techniques, alongside the expansion of genetic testing facilities in India, is likely to enhance the screening processes further, ultimately contributing to better healthcare outcomes. As the Indian healthcare ecosystem continues to advance, the focus on these two segments is expected to grow, reflecting trends that prioritize genetic insights in drug safety profiling.Â
Overall, both Gene KCNH2 and Mutant KCNH2 not only serve as pivotal players in the HERG Screening Market but also highlight the broader commitment to improving patient safety and enhancing therapeutic efficacy across India's diverse population. The market's adaptability to emerging technologies and shifting healthcare priorities positions it well for long-term growth within the evolving landscape.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The India hERG Screening Market, focused on the Ion Channel segment, is experiencing significant growth, driven by the increasing demand for effective cardiotoxicity testing methods in drug development. This segment encompasses various key components, such as voltage-gated and ligand-gated ion channels, both playing pivotal roles in cellular activities and pharmaceutical interventions. Voltage-gated ion channels are crucial for generating action potentials in cardiac tissues, thereby influencing heart rhythms, while ligand-gated ion channels are instrumental in mediating neurotransmission and muscle contractions.
The importance of these channels is underscored by their direct implications in heart-related disorders, making them essential targets in HERG screening. As research in the field expands, a deeper understanding of these channels can enhance drug safety profiles and improve therapeutic outcomes, emphasizing the significance of the Ion Channel segment in the broader context of the India hERG Screening Market. Given the rise in cardiovascular diseases and drugs that may alter cardiac function, there is an urgent need for effective screening processes, presenting ample opportunities for advancements in this segment.
The Application segment of the India hERG Screening Market is crucial for ensuring the safety and efficacy of various pharmaceutical products, particularly in the assessment of drug-induced cardiovascular risks. Antiarrhythmic drugs are pivotal in managing heart rhythm disorders, prompting rigorous HERG Screening to prevent adverse cardiac events. Antipsychotic medications, increasingly utilized in mental health treatment across India, also necessitate thorough HERG evaluations due to their impact on cardiac health. Antibiotics are significant in this market as they expand their usage, underscoring the need to understand their potential cardiotoxic effects.
Additionally, the "Others" category encompasses a diverse range of drugs, enhancing the market's breadth and complexity. Given the rising prevalence of chronic diseases and shifting drug development patterns, the demand for effective HERG Screening processes in these applications is expected to grow, driving innovation and ensuring patient safety within India's healthcare landscape. The integration of advanced technologies in drug testing and regulatory support will further bolster the overall industry, making the Application aspect a vital component of the India hERG Screening Market.
India hERG Screening Market Key Players and Competitive Insights:
The India hERG Screening Market is characterized by a rapidly evolving landscape driven by the increasing need for efficient cardiac risk assessment tools, alongside advancements in diagnostic technologies. This market has gained significant traction due to the rising prevalence of cardiovascular diseases and the focus on preventive healthcare measures. As healthcare providers in India seek to enhance patient outcomes, the demand for HERG Screening solutions has surged, leading to a competitive environment that features various players vying for market share. A range of products and innovative solutions are being introduced to meet the diverse needs of healthcare institutions, resulting in a dynamic interplay of technology, regulatory compliance, and customer service.
Siemens Healthineers holds a significant presence in the India hERG Screening Market, benefiting from its strong global reputation and extensive portfolio of diagnostic imaging and laboratory diagnostics solutions. The company focuses on providing high-quality HERG Screening technologies that are tailored to the specific health care needs of Indian populations. Siemens Healthineers leverages its innovative research and development to introduce advanced solutions that prioritize efficiency and accuracy in cardiac screening, aligning with the growing demands of healthcare providers in India. The company's established distribution networks, customer support systems, and robust partnerships with local healthcare entities further enhance its market competitiveness in this sector.
Schiller has emerged as a noteworthy player in the India hERG Screening Market, bringing unique strengths and an array of products tailored for the cardiac diagnostics segment. The company's portfolio includes advanced echocardiography devices and electrocardiogram (ECG) monitoring systems, which are crucial for comprehensive HERG screening. Schiller has been proactive in establishing its market presence through local collaborations and strategic partnerships, which help in understanding the local healthcare landscape and consumer needs.Â
In addition, the company has expanded its footprint through various mergers and acquisitions aimed at strengthening its technology offerings and market reach within India. Schiller's emphasis on innovation, reliability, and customer-centric services positions it advantageously to cater to the growing demand for HERG Screening solutions and enhances its competitive standing in the market.
Key Companies in the India hERG Screening Market Include:
India hERG Screening Market Industry Developments
In recent months, the India HERG (High-Efficiency Respiratory/Gastrointestinal) Screening Market has witnessed notable developments, particularly with companies like Siemens Healthineers, Philips Healthcare, and GE Healthcare expanding their product offerings. For instance, Siemens Healthineers announced the launch of new imaging solutions in August 2023 aimed at enhancing diagnostic accuracy. Meanwhile, Philips Healthcare's recent acquisition of a local startup in September 2023 has strengthened its presence in the Indian market, allowing for innovation in patient management technologies.Â
Also, Skanray Technologies has been focusing on developing cost-effective HERG Screening solutions tailored for the Indian healthcare landscape. In the last two to three years, the market has grown significantly, notably in March 2022, when the Indian government emphasized enhancing healthcare infrastructure, which positively impacted market valuations. Companies like BPL Medical Technologies have reported a surge in demand for advanced screening tools in line with government initiatives to improve diagnostic capabilities. As the market evolves, partnerships among these key players, along with increased investment in Research and Development, are expected to drive further growth in the HERG Screening domain within India.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 50.0(USD Million) |
| MARKET SIZE 2024 | 56.0(USD Million) |
| MARKET SIZE 2035 | 280.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.756% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Siemens Healthineers, Schiller, Philips Healthcare, Skanray Technologies, Concordia Healthcare, Nipro, MediSys, Hewlett Packard Enterprise, BPL Medical Technologies, Vyaire Medical, Mindray, GE Healthcare, Cardinal Health, Dragerwerk, Honeywell |
| SEGMENTS COVERED | Type, Ion Channel, Application |
| KEY MARKET OPPORTUNITIES | Rapid growth in pharmaceutical R&D, Rising prevalence of cardiac disorders, Increasing regulatory requirements for drug approval, Technological advancements in screening methods, Collaborations with biotech companies |
| KEY MARKET DYNAMICS | growing cardiovascular disease prevalence, increasing regulatory requirements, technological advancements in screening, rising healthcare expenditure, awareness of drug safety |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India HERG Screening Market is expected to be valued at 56.0 USD Million in 2024.
By 2035, the India HERG Screening Market is projected to reach 280.0 USD Million.
The expected CAGR for the India HERG Screening Market during this period is 15.756 percent.
The Gene KCNH2 segment is valued at 25.0 USD Million in 2024.
By 2035, the Gene KCNH2 segment is expected to be valued at 125.0 USD Million.
The Mutant KCNH2 segment is valued at 31.0 USD Million in 2024.
The Mutant KCNH2 segment is projected to reach 155.0 USD Million by 2035.
Major players include Siemens Healthineers, Philips Healthcare, and GE Healthcare among others.
Key growth drivers include advancements in technology and increasing demand for cardiac health assessment.
Current global conflicts may introduce uncertainties impacting supply chains and growth projections for the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
